Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide ...

"It is currently unclear how useful the Labcorp test will be in accurately ... patient predicted to have preeclampsia from a blood test early in pregnancy as opposed to clinical factors," Zahn ...

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...

Labcorp plans to talk with physicians and maternal-fetal specialists about the components of the test, Caveney said, but he added that the screening test could still be ordered using the blood ...

If a person would prefer to have their test in person, they can visit a Labcorp testing center. There, a healthcare professional will collect the required blood sample. This may suit people who ...

Labcorp is now offering a blood-based biomarker test in the U.S. to support the diagnosis of Alzheimer's disease. The immunoassay measures the ratio of ptau-217 and beta amyloid 42, two distinct ...

(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET ...